COVID-19 treatment-induced neuropsychiatric adverse effects
COVID-19 represents a major challenge in the field of psychiatry, as both the virus and the medications used to treat it may induce neurologic and psychiatric symptoms. Antiretroviral drugs used for the treatment of COVID-19 may produce undesirable effects on the central and peripheral nervous systems. Cytochrome p450 enzymes are affected by protease inhibitors which […]
Cariprazine as a treatment option for depressive episodes associated with bipolar 1 disorder in adults
Depressive episodes are the most frequent episodes in bipolar disorder. Few treatments, however, have been approved by the FDA for the treatment of bipolar depression. Cariprazine, a broad-spectrum dopamine antagonist/partial agonist with dopamine D3/D2 and serotonin 5-HT1A receptor partial agonist properties, was recently approved. Partial agonism/antagonism at D3 receptors inhibits the activity of somatodendritic D3 […]